Compare GSK plc (GSK) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Snap Inc — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while Snap Inc trades at $5.97 (market cap $9.83B). The key difference: GSK plc is far larger — about 9.3× Snap Inc's market cap, and GSK plc pays a 3.9% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Snap Inc for 68 Days on average.
| GSK | SNAP | |
|---|---|---|
Market Cap | $91.88B | $9.83B |
Volume | 7,730,529 | 28,532,342 |
Sector | Health | Media |
52-Week High | $61.18 | $9.09 |
52-Week Low | $43.24 | $3.93 |
Typical Hold Time | 93 Days | 68 Days |
Enterprise Value | $111.88B | $11.39B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
SNAP trades at $5.81, up 0.17% on the day, with a bullish technical signal from moving averages. The company reported revenue of $5.93B in 2025, with a net loss narrowing to -$460M, improving its profit margin to -7.77%. Recent news highlights Snap's push into enterprise AR glasses with NVIDIA and Salesforce partnerships, driving investor optimism.
The outlook remains cautious as SNAP continues to post losses despite revenue growth. Analyst consensus is a 'Hold' with a $7.78 price target, suggesting modest upside. Key risks include intense competition, regulatory pressures, and the challenge of achieving profitability. The stock's valuation appears stretched with a high EV/EBITDA of 1,149.99.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
